Clinical Pharmacology · Acid Control and Ulcer Medications
Helicobacter pylori Therapy
On this page 6 sections
In 30 seconds
Helicobacter pylori is a spiral, acid-tolerant bacterium that causes most peptic ulcers and raises the risk of gastric adenocarcinoma and gastric MALT lymphoma. It survives stomach acid via urease, an enzyme that also underlies urea breath testing and rapid urease testing. Curing it always requires several antibiotics plus acid suppression together, never one drug alone, and regimen choice depends on local resistance, allergy history, and pill-burden tolerance.
The college version
Why H. pylori Matters
H. pylori colonizes gastric mucus, causing chronic inflammation that erodes mucosal defenses and is the dominant cause of both duodenal and gastric ulcers, outweighing NSAID use worldwide. Persistent infection drives progression toward atrophic gastritis and intestinal metaplasia, raising gastric cancer risk, and it is the main driver of gastric MALT lymphoma, which can regress with eradication alone.
Urease: Survival Trick and Diagnostic Basis
Gastric acid is normally lethal to bacteria, but H. pylori's urease splits urea into ammonia and carbon dioxide, buffering acid around the organism and creating a habitable pocket within the mucus. This chemistry is exploited diagnostically: the urea breath test detects labeled carbon dioxide after ingested labeled urea, and the rapid urease test applies a biopsy sample to a pH-sensitive reagent that changes color when urease acts. Both can give false negatives if acid-suppressing or bismuth agents recently reduced bacterial activity, so these must be withheld first.
Why Combination Therapy Is Required
No single antibiotic reliably eradicates H. pylori: its mucus niche limits drug penetration, and monotherapy quickly selects for resistance. Acid suppression is paired with antibiotics for two reasons — several antibiotics degrade at low pH, and the organism is more metabolically active and susceptible at higher pH, since acid stress pushes it toward a dormant, less vulnerable state.
Regimen Families
Bismuth quadruple therapy pairs a proton pump inhibitor with bismuth, tetracycline, and a nitroimidazole such as metronidazole; bismuth adds antibacterial and mucosal-protective effects. Clarithromycin triple therapy combines a proton pump inhibitor with clarithromycin plus amoxicillin or metronidazole, reasonable only where local clarithromycin resistance is low. Newer options include rifabutin-based regimens for prior failures and regimens built around potassium-competitive acid blockers, which suppress acid more profoundly than standard proton pump inhibitors.
Why Clarithromycin Triple Therapy Has Declined
Widespread prior macrolide use for unrelated infections has left many populations with substantial clarithromycin-resistant H. pylori. One resistant mutation can defeat the whole regimen, since the other two drugs alone are not curative — pushing many guidelines toward bismuth quadruple therapy as first-line where resistance data are unavailable.
Practical Challenges and Adherence
These regimens involve many pills across multiple daily doses, and adherence is the single biggest determinant of both cure and future resistance. Side effects are common: gastrointestinal upset, a metallic taste with clarithromycin, photosensitivity with tetracyclines, and harmless black stool and tongue discoloration with bismuth. Metronidazole causes a disulfiram-like reaction with alcohol — flushing, nausea, palpitations — so alcohol must be avoided throughout.
Confirming Eradication and Allergy Considerations
Eradication should be confirmed with urea breath or stool antigen testing after therapy completes, and proton pump inhibitors and bismuth must be stopped beforehand to prevent false negatives from suppressed but not eradicated bacteria. Patients with true penicillin allergy cannot receive amoxicillin, shifting choice toward bismuth quadruple therapy or a clarithromycin-metronidazole combination.

Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine a tiny troublemaker in your stomach that makes its own bubble of "safe zone" so acid can't dissolve it. That trick is a chemical reaction, and doctors can test for that same reaction on your breath to know if the troublemaker is there. Because it's so well protected, one medicine alone can't beat it — doctors send in several medicine helpers at once, plus something that turns down the acid so the helpers work better. It's like needing several friends working together, with the lights turned up, to catch a hider instead of sending one friend into the dark alone.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient finishes H. pylori therapy and wants a urea breath test the next day while still taking a proton pump inhibitor. Why might this plan give a misleading result?
Show answer
Still on a PPI, breath test can be falsely negative
Staying on a proton pump inhibitor suppresses bacterial activity and urease production without necessarily killing every organism, so the test can look clean even though bacteria remain.
A patient has a documented penicillin allergy and needs H. pylori treatment. What does this mean for regimen selection, and what alternative is reasonable?
Show answer
Avoid amoxicillin, use bismuth quadruple or clarithromycin-metronidazole
Because amoxicillin is a penicillin, it should be avoided entirely, so the reasonable path is bismuth quadruple therapy or a regimen pairing clarithromycin with metronidazole instead.
Quick check
3 questions here. Answers stay hidden until you check.
What is the primary reason proton pump inhibitors are combined with antibiotics in H. pylori therapy?
Which finding explains why clarithromycin triple therapy has fallen out of favor in many regions?
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.

